Boston Scientific Q2 FY26: where the revenue came from and where it went
The whole income statement of Boston Scientific for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Apr 1 – Jun 30, 2026
- Reported
- Aug 3, 2026
Revenue$5.44B
+8% year over year
Gross profit$3.85B
71% margin
Operating profit$1.18B
22% margin
Net profit$0.91B
17% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 5.44 | 100% | +8% |
| Cardiology therapies | 1.33 | 24% | |
| Electrophysiology | 0.92 | 17% | +9% |
| Global endoscopy | 0.79 | 15% | +8% |
| Urology & pelvic health | 0.68 | 13% | +1% |
| Cardiac rhythm management | 0.59 | 11% | −1% |
| Watchman | 0.51 | 9% | +4% |
| Neuromodulation | 0.34 | 6% | +13% |
| Interventional oncology | 0.28 | 5% | |
| Cost of revenue | −1.59 | 29% | |
| Gross profit | 3.85 | 71% margin | +3pp |
| SG&A | −1.80 | 33% | −1pp |
| Other | −0.87 | 16% | +0pp |
| Operating profit | 1.18 | 22% margin | +5pp |
| Interest & other costs | −0.12 | ||
| Tax | −0.16 | ||
| Net profit | 0.91 | 17% margin | +1pp |
182 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest